Aripiprazole Tablet, Orally Disintegrating
Product Images NDC 59651-515

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 59651-515). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Aripiprazole Fig1)

This text provides information on the effect of various drugs on Aripiprazole, including CYP3A4 Inhibitor ketoconazole, CYP2D6 Inhibitor quinidine, CYP3M Inducer carbamazepine, Gastric Acid Reducer famotidine, and Others such as valproate, lithium, and lorazepam. The text also mentions Aripiprazole Fold Changes and 90% Confidence Intervals for different interacting drugs.*

FDA Label Image

Package Label.principal Display Panel (10 mg (30 Tablets Bottle))

This is a description of a medication labeled as Aripiprazole Orally Disintegrating Tablets, USP. Each bottle contains 30 tablets, with each tablet containing 10 mg of Aripiprazole USP. The pharmacist is instructed to dispense a Medication Guide along with the tablets to each patient. Patients should refer to the package insert for information on indications and dosage. It contains phenylalanine, and should be stored at 20° to 25°C. The medication is distributed by Aurobindo Pharma USA, Inc., and it is made in India.*

FDA Label Image

Package Label.principal Display Panel (10 mg Carton (3 x 10 Unit-dose))

This text is a product description for Aripiprazole Orally Disintegrating Tablets, USP. It includes information about the packaging, dosage, storage instructions, and pharmacist guidance for dispensing. The product is manufactured by Aurobindo Pharma U.S.A., Inc. and is available in unit-dose packaging containing 30 tablets. It also provides the National Drug Code (NDC) for identification.*

FDA Label Image

Package Label.principal Display Panel (15 mg (30 Tablets Bottle))

This is the description: Each orally disintegrating tablet contains Aripiprazole USP 15 mg. It is distributed by Aurobindo Pharma USA, Inc. The tablets are meant for prescription use only and should be stored at 20° to 26°C. The medication guide should be dispensed separately to each patient. For more information, visit www.aurobindousa.com/medication.*

FDA Label Image

Package Label.principal Display Panel (15 mg Carton (3 x 10 Unit-dose))

FDA Label Image

Fig2 (Aripiprazole Fig2)

This text appears to list the effects of other drugs on Aripiprazole, specifically focusing on PK Dehydro-Aripiprazole and fold change with a 90% confidence interval. The mentioned drugs include Ketoconazole, a CYP2D6 inhibitor like quinidine, a CYP3A inducer such as carbamazepine, famotidine as a Gasri Acid Blocker, and other drugs like valproate, lithium, and lorazepam. The text seems to show changes relative to the reference without the interacting drug.*

FDA Label Image

Fig3 (Aripiprazole Fig3)

The text provided seems to contain information about the effect of Aripiprazole on other drugs and their interactions. It includes names of various drugs and mentions fold change with a reference to the 90% confidence interval. The data appears to be related to pharmacokinetics and drug interactions.*

FDA Label Image

Fig4 (Aripiprazole Fig4)

Special Populations This text seems to contain data related to special populations, with information on age, gender, and different measurements like Hapaic Implement, Avipiprazole Fold Change, and 90% CI. It also mentions comparison between mild vs. normal motete and some values like 05, 20, 75, and 30. This data could be used for research or analysis on specific population groups.*

FDA Label Image

Fig5 (Aripiprazole Fig5)

This description is not readable.*

FDA Label Image

Fig6 (Aripiprazole Fig6)

This text provides information on the proportion with relapse and the number of subjects at risk over a period of time, measured in days from randomization. The data seems to be categorized or organized based on different time points or subjects.*

FDA Label Image

Fig (Aripiprazole Fig7)

This document appears to be a table showing the proportion with relapse over time for subjects taking Aripiprazole versus Placebo. The table plots the number of subjects at risk for each time point, from day 0 to day 182, as well as the corresponding number of subjects experiencing relapse.*

FDA Label Image

Figure 8 (Aripiprazole Fig8)

FDA Label Image

Figure 9 (Aripiprazole Fig9)

This is a chart showing the change in YGTSS total tic score from baseline in a study comparing aripiprazole low dose, aripiprazole high dose, and placebo over the course of treatment weeks.*

FDA Label Image

Str (Aripiprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.